Literature DB >> 7376884

Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man.

O E Almersjö, B G Gustavsson, C G Regårdh, P Wåhlén.   

Abstract

The pharmacokinetic conditions for oral administration of 5-fluorouracil (5-FU) were investigated in 16 patients with malignant liver tumours. The concentration of 5-FU in portal and systemic blood was determined by a microbiologic method every 10 min. during 2 hours after oral or intravenous administration of a standard dose of 250 mg 5-FU ( approximately 4 mg/kg b. wt.) or 15 mg 5-FU/kg b. wt. The drug was rapidly absorbed after oral administration with peak values within 10-30 min. 25% of the lower and 40% of the higher oral dose reached the systemic circulation. The reduction of systemic bio-availability was partly accomplished by a loss in the gastrointestinal tract and partly by extraction by the liver. The hepatic extraction ratio was calculated to 0.56 and 0.26 after the lower and the higher dose respectively indicating a saturable process. The availability of 5-FU was significantly higher in portal blood than in systemic blood after oral administration. The opposite conditions were found after intravenous administration. Thus, oral administration of 5-FU to patients with malignant liver tumours seems rational.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7376884     DOI: 10.1111/j.1600-0773.1980.tb02463.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  6 in total

Review 1.  5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.

Authors:  J L Grem
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

2.  Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva.

Authors:  L A Celio; G J DiGregorio; E Ruch; J Pace; A J Piraino
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Regional and systemic serum concentrations of 5-fluorouracil after portal and intravenous infusion: an experimental study in dogs.

Authors:  B G Gustavsson; A Brandberg; C G Regårdh; O E Almersjö
Journal:  J Pharmacokinet Biopharm       Date:  1979-12

Review 4.  Clinical pharmacokinetic advantages of new drug delivery methods for the treatment of liver tumours.

Authors:  J H Anderson; H W Warren; C S McArdle
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

5.  Cardiopulmonary hemodynamics and pharmacokinetics after hepatic intraarterial infusion of 5-fluorouracil (5-FU). An experimental study in the pig.

Authors:  M Andersson; L Domellöf; S Häggmark; G Johansson; S Reiz; B Gustavsson
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids.

Authors:  Jie Cui; Ya-Huan Guo; Hong-Yi Zhang; Li-Li Jiang; Jie-Qun Ma; Wen-Juan Wang; Min-Cong Wang; Cheng-Cheng Yang; Ke-Jun Nan; Li-Ping Song
Journal:  Onco Targets Ther       Date:  2014-02-24       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.